Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

REVLIMID-R-CHOP Phase I/II data in untreated DLBCL presented at malignant lymphoma conference

REVLIMID-R-CHOP Phase I/II data in untreated DLBCL presented at malignant lymphoma conference

New Australian drug shows positive response in patients with multiple myeloma blood cancer

New Australian drug shows positive response in patients with multiple myeloma blood cancer

Seattle Genetics brentuximab vedotin, dacetuzumab clinical data to be presented at ICML 2011

Seattle Genetics brentuximab vedotin, dacetuzumab clinical data to be presented at ICML 2011

Millennium reports results from two MLN9708 ongoing Phase I studies on multiple myeloma

Millennium reports results from two MLN9708 ongoing Phase I studies on multiple myeloma

Millennium reports results from two VELCADE based combination studies against multiple myeloma

Millennium reports results from two VELCADE based combination studies against multiple myeloma

Celgene announces results of REVLIMID, docetaxel/prednisone phase II combination study on mCRPC

Celgene announces results of REVLIMID, docetaxel/prednisone phase II combination study on mCRPC

ImmunoGen's IMGN901 Phase I trial data on multiple myeloma presented at ASCO 2011

ImmunoGen's IMGN901 Phase I trial data on multiple myeloma presented at ASCO 2011

EntreMed's ENMD-2076 Phase 2 trial data on platinum-resistant ovarian cancer presented at ASCO 2011

EntreMed's ENMD-2076 Phase 2 trial data on platinum-resistant ovarian cancer presented at ASCO 2011

ZYTIGA clinical study data on prostate cancer to be presented at ASCO 2011

ZYTIGA clinical study data on prostate cancer to be presented at ASCO 2011

VCU Massey completes Bortezomib-Alvocidib Phase I clinical trial against blood cancers

VCU Massey completes Bortezomib-Alvocidib Phase I clinical trial against blood cancers

XTL receives FDA Orphan-drug designation for rHuEPO drug to treat Multiple Myeloma

XTL receives FDA Orphan-drug designation for rHuEPO drug to treat Multiple Myeloma

Adaptimmune announces opening of Phase I/II clinical trial in multiple myeloma

Adaptimmune announces opening of Phase I/II clinical trial in multiple myeloma

ImmunoGen's clinical data on IMGN901 and SAR3419 to be presented at ASCO 2011

ImmunoGen's clinical data on IMGN901 and SAR3419 to be presented at ASCO 2011

NEJM publishes ZYTIGA plus prednisone Phase 3 trial data in metastatic castration-resistant prostate cancer

NEJM publishes ZYTIGA plus prednisone Phase 3 trial data in metastatic castration-resistant prostate cancer

New findings from STELARA psoriasis clinical trial to be presented at 22nd World Congress of Dermatology

New findings from STELARA psoriasis clinical trial to be presented at 22nd World Congress of Dermatology

Lilly Phase I multiple myeloma study affirms potential of LY2127399-bortezomib combination

Lilly Phase I multiple myeloma study affirms potential of LY2127399-bortezomib combination

Bristol-Myers Squibb to present abstracts on oncology compounds at ASCO 2011 Annual Meeting

Bristol-Myers Squibb to present abstracts on oncology compounds at ASCO 2011 Annual Meeting

EMA CHMP recommends positive opinion for marketing authorization of Amgen's XGEVA

EMA CHMP recommends positive opinion for marketing authorization of Amgen's XGEVA

Bayer, Onyx to present Nexavar-chemotherapy combination Phase 2b trial data in breast cancer at ASCO 2011

Bayer, Onyx to present Nexavar-chemotherapy combination Phase 2b trial data in breast cancer at ASCO 2011

Positive results from Onyx's carfilzomib Phase 2b 003-A1 study in relapsed and refractory multiple myeloma

Positive results from Onyx's carfilzomib Phase 2b 003-A1 study in relapsed and refractory multiple myeloma

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.